ArticleCureus2026
A Swift Solution: Early Removal of the JADA Device in the Management of Postpartum Hemorrhage.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postpartum hemorrhage (PPH) continues to be a major threat to maternal health worldwide. Current management strategies include uterotonic agents, intrauterine tamponade devices, and surgical interventions. These methods have variable efficacy, carry potential complications, and contribute to significant healthcare costs. The JADA device is an emerging and promising tool for managing PPH. We report the case of a 19-year-old G2P1011 at 39w3d who experienced uterine atony following a spontaneous vaginal delivery. Despite administration of Pitocin and tranexamic acid, the patient continued to have brisk vaginal bleeding after placental delivery. She was subsequently transferred to the OR for an exam under anesthesia due to her intolerance of pelvic examinations. Uterine atony was confirmed, and a second-degree perineal laceration with minimal bleeding was noted. The decision was made to place a JADA device when the bleeding did not resolve with uterotonics and bimanual massage. The second-degree perineal laceration was repaired in standard fashion. The JADA device was successfully removed after 30 minutes, rather than the manufacturer-recommended one-hour duration. Total quantified blood loss was 1300 mL. The patient was stable for discharge on postoperative day 2 and had an uncomplicated postoperative and postpartum course despite early removal of the JADA device. This case highlights the efficacy and safety of early JADA removal in the management of PPH. Recent data suggest that the JADA offers distinct advantages over traditional tamponade devices such as the Bakri balloon. The device's versatility may be particularly beneficial in settings where prolonged placement is not feasible. Beyond obstetrics, the JADA device has shown potential in gynecologic procedures, such as after myomectomies. Overall, the JADA device offers a safe, effective, and versatile tool for PPH management. This case contributes to the growing evidence supporting its role in individualized care and underscores the need for further studies exploring early removal protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.